Euroopa Liit - eesti - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - telmisartan - hüpertensioon - angiotensiin ii antagonistid, tavaline - hypertensiontreatment oluline hüpertensioon täiskasvanutel. südame-veresoonkonna preventionreduction südame-veresoonkonna haiguste patsientidel:manifest atherothrombotic südame-veresoonkonna haigus (anamneesis südame isheemiatõbi, insult või perifeersete arterite haigus) või;tüüp-2 diabeet koos dokumenteeritud eesmärk-elundite kahjustused.

Eesti - eesti - Ravimiamet

krka d.d. novo mesto - vardenafiil - õhukese polümeerikattega tablett - 5mg 2tk; 5mg 4tk; 5mg 20tk

Eesti - eesti - Ravimiamet

krka d.d. novo mesto - vardenafiil - õhukese polümeerikattega tablett - 10mg 12tk; 10mg 2tk; 10mg 8tk; 10mg 4tk

Eesti - eesti - Ravimiamet

krka d.d. novo mesto - vardenafiil - õhukese polümeerikattega tablett - 20mg 20tk; 20mg 2tk; 20mg 4tk; 20mg 8tk; 20mg 12tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - oftalmoloogilised vahendid - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.

Eesti - eesti - Ravimiamet

viatris sia - klaritromütsiin - infusioonilahuse kontsentraadi pulber - 500mg 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan ireland limited - rivaroksabaan - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombootilised ained - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Eesti - eesti - Ravimiamet

viatris limited - lantaan - närimistablett - 750mg 90tk; 750mg 15tk

Eesti - eesti - Ravimiamet

viatris healthcare limited - lipaas+amülaas+proteaas - gastroresistentne kõvakapsel - 10000ühik+8000ühik+600ühik 100tk

Eesti - eesti - Ravimiamet

viatris healthcare limited - laktuloos - suukaudne lahus - 667mg 1ml 300ml 1tk; 667mg 1ml 15ml 20tk; 667mg 1ml 500ml 1tk; 667mg 1ml 800ml 1tk; 667mg 1ml 200ml 1tk; 667mg 1ml 1000ml 1tk